467 related articles for article (PubMed ID: 35305593)
1. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract][Full Text] [Related]
5. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
Chang X; Li X; Sun P; Li Z; Sun P; Ning S
BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
Shimozato N; Namisaki T; Okano A; Ohana M; Kinoshita D; Kawasaki T; Aihara Y; Nakatani T; Kinoshita H; Ann T; Saito KO; Yoshida M; Yoshiji H
Anticancer Res; 2022 Jan; 42(1):173-183. PubMed ID: 34969723
[TBL] [Abstract][Full Text] [Related]
8. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
9. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract][Full Text] [Related]
14. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
15. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]